MedTrace Logo

International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

NCT07420855 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 361

Last updated 2026-02-19

No results posted yet for this study

Summary

The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer.

Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.

Conditions

Sponsors & Collaborators

  • Aron Research Foundation Ets

    lead OTHER

Principal Investigators

  • Matteo Santoni · Aron Research Foundation Ets

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-11-30
Completion
2030-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07420855 on ClinicalTrials.gov